Quidel Corporation (QDEL) stock surged 7.66% in pre-market trading on Thursday, following the release of its Q4 2024 earnings report and 2025 guidance.
While the company reported a 4% year-over-year decline in Q4 2024 revenue to $708 million, primarily due to lower COVID-19 and flu testing demand, Quidel provided an optimistic outlook for 2025. The company expects revenue to range between $2.6 billion and $2.81 billion, with adjusted EBITDA guidance of $575 million to $615 million, representing a 22% margin.
Quidel's strong pre-market performance can be attributed to its ongoing cost reduction initiatives and the potential for margin improvement. The company is implementing procurement savings and other cost-cutting measures, which are expected to drive adjusted EBITDA margin expansion by 250 basis points in 2025. Additionally, Quidel highlighted positive developments such as the initiation of clinical trials for its Savanna Respiratory Panel and stable growth in its core Labs business.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。